Hydroxyzine Tablets/Capsules bulk supplier for pharma manufacturers

Hydroxyzine Tablets/Capsules Suppliers & Bulk Manufacturers

Available Forms: Tablets/Capsules

Available Strengths: 10 mg, 25 mg, 50 mg, 100 mg

Reference Brands: US: Vistaril®, , Atarax®; EU: Atarax®, Hydroxyzine Mylan®, Ucerax®

Category: Antipsychotropic Drugs

Hydroxyzine Tablets/Capsules is available in Tablets/Capsules and strengths such as 10 mg, 25 mg, 50 mg, 100 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Hydroxyzine Tablets/Capsules is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Hydroxyzine Tablets/Capsules can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description: Hydroxyzine tablets and capsules are FDA-approved in the USA for treating anxiety, tension, pruritus, and for sedation. Widely prescribed in both adults and children, labeling emphasizes dose adjustments, CNS effects, and contraindications in patients with prolonged QT interval. In the European Union, hydroxyzine is authorized under national procedures, not centralized, with restrictions in some countries due to cardiac safety concerns. EU regulations mandate clear warnings on QT prolongation, drug interactions, and age-based contraindications. Pharmacovigilance measures, including risk minimization plans, are strictly enforced. For sourcing and detailed product listings, visit Pharmatradz.com.

Frequently Asked Questions

Yes, Hydroxyzine Tablets/Capsules is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Hydroxyzine Tablets/Capsules is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details
Zuclopenthixol Short-Acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details
Zuclopenthixol Tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.